Clinical trials: Malignant Melanoma
Metastatic Melanoma
IL-17 Blockade to Decrease irAEs (REPLAY)
The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously…
- Trial name
- REPLAY (NCT07237594)
- Testing
- Secukinumab Injection
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Melanoma
PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients
There is a lack of strategies for patients who progress after responding to PD-1/l-1 in melanoma. High expression of Nectin4 in skin and melanomas may serve as a new target in advanced melanomas.
- Trial name
- PlugIN (NCT06906822)
- Testing
- enfortumab vedotin, pembrolizumab
- Where
- 13 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Recurrent Melanoma, Stage III Melanoma
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
RATIONALE: White blood cells that have been treated in a laboratory may be able to kill tumor cells in patients with melanoma. Aldesleukin and denileukin diftitox may stimulate the white blood cells to kill melanoma cells.
- Conditions
- Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT00945269
- Testing
- therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Melanoma
Nab-PCE vs PC for MM After Failure of Anti-PD-1
This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin Endostatin for advanced melanoma after failure of PD-1 therapy.
- Trial name
- NCT03917069
- Testing
- Chemotherapeutic Combinations, chemotherapy
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Peking University Cancer Hospital & Institute
Stage 0 Skin Melanoma, Stage I Skin Melanoma
Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma
This clinical trial studies how well an interactive tailored website works in promoting sun protection and skin self-check behaviors in patients with stage 0-III melanoma.
- Conditions
- Stage 0 Skin Melanoma, Stage I Skin Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma
- Trial name
- NCT03028948
- Testing
- Internet-Based Intervention, Questionnaire Administration, Survey Administration
- Where
- 2 sites in United States
- Volunteers
- 485 people
- Sponsor
- Rutgers, The State University of New Jersey
Melanoma
TNFerade™ Biologic Plus Radiation for Metastatic Melanoma
Phase II, open label study in which patients with metastatic melanoma (stage III or IV) who have cancer which is not considered curable by surgery will receive intratumoral injections of TNFerade™ plus radiation as a 4-week…
- Trial name
- NCT00261404
- Testing
- TNFerade™
- Where
- United States
- Sponsor
- GenVec
Mucosal Melanoma
Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.
This study was a one-arm, single-center, phase II clinical study. Patients who meet the enrollment criteria will receive CM082 tablets 200mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination…
- Trial name
- NCT03602547
- Testing
- CM082 plus JS001
- Where
- China
- Volunteers
- 40 people
- Sponsor
- AnewPharma
Melanoma, Metastatic Melanoma
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion.
- Conditions
- Melanoma, Metastatic Melanoma, Solid Tumor, Neoplasm
- Trial name
- NCT01425008
- Testing
- MLN2480
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 149 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Metastatic Uveal Melanoma
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been…
- Trial name
- NCT06581406
- Testing
- RP2, Ipilimumab, Nivolumab
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 280 people
- Sponsor
- Replimune, Inc.
Melanoma, Liver Metastasis
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
The goal of this clinical research is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given directly to the area where the cancer is located. The safety of this drug will also be studied.
- Trial name
- NCT00833807
- Testing
- Nab-Paclitaxel (Abraxane)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Melanoma
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
High-dose IL-2 treatment for metastatic melanoma has been approved by the FDA in 1998. Studies of GM-CSF plus IL-2 have not addressed the approved dose and schedule.
- Trial name
- NCT00616564
- Testing
- GM-CSF
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Pancreatic Neoplasms, Melanoma
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
In this national Phase I dose-escalation study the safety and tolerability of AP 12009 is evaluated in adult patients with advanced tumors known to overproduce TGF-β2, who are not or no longer amenable to established therapies.
- Conditions
- Pancreatic Neoplasms, Melanoma, Colorectal Neoplasms
- Trial name
- NCT00844064
- Testing
- AP 12009
- Where
- 10 sites in Germany
- Volunteers
- 62 people
- Sponsor
- Isarna Therapeutics GmbH
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Melanoma (Skin)
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00521001
- Testing
- everolimus, temozolomide
- Where
- 198 sites in United States
- Volunteers
- 49 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body.
- Conditions
- Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
- Trial name
- NBM-BMX-UM (NCT07136181)
- Testing
- NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novelwise Pharmaceutical Corporation
Advanced Solid Tumor, BRAF V600 Mutation
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
This is a Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in patients with BRAF V600-Mutant advanced…
- Trial name
- NCT05501912
- Testing
- ABM-1310
- Where
- 10 sites in China
- Volunteers
- 20 people
- Sponsor
- ABM Therapeutics Shanghai Company Limited
Breast Cancer, Melanoma
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular…
- Conditions
- Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
- Trial name
- NIP IT! (NCT05196087)
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- University Health Network, Toronto
Melanoma
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients
Objectives: This is an exploratory study, consisting of two parts. In part I a dose escalation is performed and the primary objective is the safety of different doses of TLR-dendritic cell (TLR-DC).
- Trial name
- NCT00940004
- Testing
- autologous dendritic cell vaccination
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Non-melanoma Skin Cancer
Comparing Pressure Versus Simple Adhesive Dressing After Mohs Reconstruction
The purpose of this study is to determine whether using a pressure- vs. simple adhesive dressing affects the postoperative course and wound healing outcomes following Mohs surgery.
- Trial name
- NCT02780934
- Testing
- Pressure Dressing, Simple Adhesive Dressing
- Volunteers
- 81 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Malignant Melanoma of Skin, Quality of Life
Employment and Quality of Life in Patients With Malignant Melanoma
Within the first year after diagnosis, data on employment and quality of life will be collected and evaluated in patients with malignant melanoma
- Conditions
- Malignant Melanoma of Skin, Quality of Life, Work Ability
- Trial name
- NCT02668887
- Testing
- Quality of Life, status of employment
- Where
- Germany
- Volunteers
- 221 people
- Sponsor
- Fachklinik Hornheide an der Universität Münster
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.